Biotech

CTD Holdings announced it enrolled the first patient in their phase 1 clinical trial evaluating the intravenous administration of Trappsol Cyclo in patients with Niemann-Pick Disease Type C.

CTD Holdings (OTCQB:CTDH) announced it enrolled the first patient in their phase 1 clinical trial evaluating the intravenous administration of Trappsol Cyclo in patients with Niemann-Pick Disease Type C.
As quoted in the press release:

NPC is a rare and fatal genetic disease that impacts the brain, lung, liver, spleen, and other organs. The first patient was enrolled at UCSF Benioff Children’s Hospital Oakland, the single site for this trial, by Dr. Caroline Hastings, pediatric hematologist and oncologist. Dr. Hastings is the Principal Investigator for the US Phase I trial.
The Phase I clinical trial will require 12 patients to be fully enrolled. It is a double-blind randomized trial evaluating two doses of Trappsol® Cyclo™, 1500 mg/kg or 2500 mg/kg, in NPC patients 18 years of age and older. Trappsol® Cyclo™ will be administered intravenously via bi-monthly injections over a period of 14 weeks.

Click here to read the full press release.

Source: www.marketwired.com

Featured

MARKETS

Markets
TSX20181.92+80.54
TSXV705.58+14.41
DOW31253.13-236.94
S&P 5003900.790.00
NASD11388.500.00
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1843.96+1.78
Silver21.79-0.11
Copper4.30+0.02
Palladium2041.78+37.77
Platinum965.50+6.50
Oil112.34+0.13
Heating Oil3.65-0.02
Natural Gas7.98-0.33

DOWNLOAD FREE REPORTS

×